Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform
05 Febbraio 2024 - 2:00PM
Business Wire
Addition of another amino acid recognizer
combined with improvements in surface chemistry, reagents and
software will offer Platinum users greater sequencing output and
coverage per sample
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the launch of new platform enhancements for Platinum®, with the
release of its new V2 Sequencing Kits. Combined with its
first-to-market, next-generation protein sequencer™, these
enhancements enable:
- Increased sequencing performance with assay improvements,
including the addition of a new amino acid recognizer;
- Ability to identify unknown proteins with advanced analytical
and inference tools;
- High reproducibility across runs; and
- Approximately a 3-fold reduction in cost per amino acid.
“Our newly introduced capabilities will provide researchers with
additional insights into the proteome that have the potential to
unlock scientific discovery only possible at the level of single
amino acid recognition” said Jeff Hawkins, Chief Executive Officer
of Quantum-Si. “With Platinum, we are striving to make protein
sequencing accessible to every lab everywhere and now, with our V2
Sequencing Kits, more insights are possible with greater cost
efficiency so that even more scientists can easily incorporate
Platinum into their workflow.”
Quantum-Si is dedicated to meeting customer needs and enhancing
their user experience. The recent launch marks an expansion of the
Company's current Platinum applications, now incorporating peptide
barcodes and accommodating new sample types.
“These advancements not only ensure increased robustness and
performance but also introduce novel protein inference analysis
software, empowering customers to discover unknown proteins in
their samples,” said Grace Johnston, Chief Commercial Officer of
Quantum-Si. “With this launch, Quantum-Si is set to deliver
unparalleled insights into protein characterization and function,
catering to the evolving needs of our diverse customer base.
Further, it reflects the value of next-generation protein
sequencing as we expect that our platform will open new doors to
unprecedented biologic insights and the molecules of life.”
The company is now accepting orders for first-time and existing
customers for the Protein Sequencing Kit V2.
In tandem with its recent announcement, the company’s CEO and
executive team have released a video outlining recent enhancements.
Jeff Hawkins will highlight the significance of the newly launched
kits and outlines strategic initiatives for 2024. To connect with
the visionaries driving the proteomics advancements, watch the
video here.
For more information on Platinum, visit quantum-si.com.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at quantum-si.com or
follow us on LinkedIn or X (formerly Twitter).
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the inability to maintain the
listing of the Company's Class A common stock on The Nasdaq Stock
Market; the ability of the Company to grow and manage growth
profitably and retain its key employees; the Company’s ongoing
leadership transitions; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum™ protein
sequencing instrument and kits and the Company’s other products
once commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240205654561/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com
Media Contact Katherine Atkinson, SVP of Commercial
Marketing media@quantum-si.com
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Ott 2023 a Ott 2024